Caxton Associates (New York)’s Affimed AFMD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
Sell
-8,907
Closed -$110K 484
2022
Q4
$110K Buy
8,907
+825
+10% +$14.5K 0.01% 418
2022
Q3
$166K Buy
8,082
+6,611
+449% +$184K 0.02% 416
2022
Q2
$41K Buy
+1,471
New +$50.4K ﹤0.01% 537

Other funds holding AFMD

Caxton Associates (New York)'s AFMD Position: Q1 2023 in Review

Caxton Associates (New York) sold out of Affimed (AFMD) in Q1 2023, closing a stake of 8,907 shares — an estimated $110K sold.

Caxton Associates (New York) first reported a position in AFMD in Q2 2022 and held it in 3 quarters. The position peaked at $166K in Q3 2022. 94 funds tracked by Wall St. Rank hold AFMD as of Q1 2023.

  • Caxton Associates (New York) reported no remaining Affimed position as of Q1 2023 after selling out during the quarter.
  • Caxton Associates (New York) sold 8,907 Affimed shares in Q1 2023, an estimated $110K.
  • Caxton Associates (New York) first reported a position in Affimed in Q2 2022 and held it in 3 quarters.
  • Caxton Associates (New York)'s Affimed position peaked at $166K in Q3 2022.
  • 94 funds tracked by Wall St. Rank held Affimed as of Q1 2023.

Based on Caxton Associates (New York)'s 13F filing for Q1 2023, filed 15 May 2023.